BioSpace News Archive

Genentech announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ®.

Brammer Bio announces recent leadership appointments to support the growth of the organization.

The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.

Oxford Nanopore Technologies Ltd has raised £100M ($140M) in new investment.

Evolva posted its financial results today for the period from 1 January to 31 December 2017, and provided business highlights that illustrate how the Company is executing on its strategic transformation plan which was put in place last August.

Supplemental Health Care is proud to earn the “Best Place to Work” award in the large-sized company category by Buffalo Business First, a leading business publication in the region.

Essity has today published its Annual and Sustainability Report for 2017, available on www.essity.com.

This opportunity adds the Kent device to Allegan Canada’s Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®, Natrelle®, Revolve®, and the Keller Funnel®.

For a second year, dentists topped the list of health practitioners Americans want to see more often, according to a survey from Delta Dental.

Bayer and Ginkgo Bioworks announced the official name of its joint venture, Joyn Bio.